Suppr超能文献

F 型红细胞促进镰状细胞病中的疟原虫增殖。

F-erythrocytes promote Plasmodium falciparum proliferation in sickle cell disease.

机构信息

Pediatric Hematology/Oncology Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

出版信息

Am J Hematol. 2023 Oct;98(10):1598-1605. doi: 10.1002/ajh.27042. Epub 2023 Aug 16.

Abstract

BACKGROUND

Sickle cell disease (SCD) remains prevalent because heterozygous carriers (HbAS) are partially resistant to Plasmodium falciparum malaria. Sickle hemoglobin (HbS) polymerization in low and intermediate oxygen (O ) conditions is the main driver of HbAS-driven resistance to P. falciparum malaria. However, epidemiological studies have reported mixed malaria morbidity and mortality outcomes in individuals with sickle cell disease (SCD). While maximum-tolerated dose hydroxyurea has been shown to lower malaria incidence, fetal hemoglobin (HbF), an inhibitor of HbS polymerization that is variably packaged in F-erythrocytes, might provide hemoglobin that is accessible to the parasite for feeding.

METHODS

To explore that risk, we examined the effect of variable mean corpuscular fetal hemoglobin (MCHF) on P. falciparum proliferation, invasion, and development in HbSS RBCs.

RESULTS

We found that greater MCHF in HbSS red blood cells (RBCs) is associated with increased P. falciparum proliferation in O environments comparable with the microcirculation. Moreover, both parasite invasion and intracellular growth, the major components of proliferation, occur predominantly in F-erythrocytes and are augmented with increasing MCHF.

CONCLUSIONS

HbF modifies P. falciparum infection in HbSS RBCs, further highlighting the complexity of the molecular interactions between these two diseases. Other inhibitors of HbS polymerization that do not increase HbF or F-erythrocytes should be independently assessed for their effects on P. falciparum malaria proliferation in HbSS RBCs.

摘要

背景

镰状细胞病(SCD)仍然很普遍,因为杂合子携带者(HbAS)对恶性疟原虫疟疾有一定的抵抗力。低氧和中间氧条件下的镰状血红蛋白(HbS)聚合是 HbAS 驱动对恶性疟原虫疟疾抗性的主要驱动因素。然而,流行病学研究报告称,镰状细胞病(SCD)个体的疟疾发病率和死亡率存在混合结果。虽然最大耐受剂量羟基脲已被证明可以降低疟疾发病率,但胎儿血红蛋白(HbF)作为 HbS 聚合的抑制剂,其在 F-红细胞中的包装是可变的,可能提供可被寄生虫摄取的血红蛋白以供摄取。

方法

为了探索这种风险,我们研究了可变平均红细胞内胎儿血红蛋白(MCHF)对 HbSS 红细胞中恶性疟原虫增殖、入侵和发育的影响。

结果

我们发现 HbSS 红细胞中的 MCHF 增加与在类似于微循环的 O 环境中恶性疟原虫的增殖增加有关。此外,寄生虫入侵和细胞内生长(增殖的主要组成部分)主要发生在 F-红细胞中,并随着 MCHF 的增加而增加。

结论

HbF 改变了 HbSS 红细胞中的恶性疟原虫感染,进一步突出了这两种疾病之间分子相互作用的复杂性。其他不增加 HbF 或 F-红细胞的 HbS 聚合抑制剂应独立评估其对 HbSS 红细胞中恶性疟原虫疟疾增殖的影响。

相似文献

2
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲(羟脲)治疗镰状细胞病。
Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3.
5
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲(羟基脲素)用于镰状细胞病。
Cochrane Database Syst Rev. 2017 Apr 20;4(4):CD002202. doi: 10.1002/14651858.CD002202.pub2.
8
Primaquine for reducing Plasmodium falciparum transmission.伯氨喹用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD008152. doi: 10.1002/14651858.CD008152.pub2.

本文引用的文献

3
High incidence of malaria in patients with sickle cell disease.镰状细胞病患者疟疾发病率高。
Am J Hematol. 2022 Oct;97(10):E380-E381. doi: 10.1002/ajh.26676. Epub 2022 Aug 17.
6
Deconstructing the parasite multiplication rate of Plasmodium falciparum.解析疟原虫裂殖子繁殖率。
Trends Parasitol. 2021 Oct;37(10):922-932. doi: 10.1016/j.pt.2021.05.001. Epub 2021 Jun 10.
7
Post-Transcriptional Genetic Silencing of to Treat Sickle Cell Disease.用 治疗镰状细胞病的转录后基因沉默。
N Engl J Med. 2021 Jan 21;384(3):205-215. doi: 10.1056/NEJMoa2029392. Epub 2020 Dec 5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验